IMPACT 2012: Product Theater Information

2012_IMPACT_logo

 

About IMPACT'S Product Theaters

Product Theaters are 45-minute sessions that provide a focused high-value live marketing opportunity for corporate partners to reach motivated professionals in a pre-scheduled, private session held in the Metro Toronto Convention Centre. These unopposed sessions are scheduled throughout the day. Product Theaters provide a forum to gather and discuss issues on patient education, specific products and therapeutic areas with company representatives or your designees. Provide information to the audience on a subject of your choice, showcase products, services or new clinical science. AAPA recognizes that the Product Theater(s) will be promotional and may concentrate on a specific product or drug. These sessions are not approved for CME credit.

2012 Product Theater Schedule:

Sunday, May 27

 

Lunch Product Theaters

 

12 - 12:45 p.m.

Steadying the Course: Maintaining Remission in UC with Once-Daily Therapy

Speaker: Kate Adis, MS, R-PAC

Presented by: Salix Pharmaceuticals, Inc.

701 AB, Metro Toronto Convention Centre

 

Flare-ups of ulcerative colitis (UC) and their characteristic symptoms of diarrhea and rectal bleeding are painful and disruptive, undermining health and interfering with activities of daily living. Flare-ups may occur after months of remission. This program will examine the key clinical
factors in choosing among treatments to maintain remission, focusing on the safety and efficacy of a locally acting, once-daily aminosalicylate (5-ASA) approved for maintenance of remission in adult patients with UC.

 

12 - 12:45 p.m.

Reevaluating Overall Diabetes Management: It’s Not Just About A1C

Speaker: Christopher Sadler, MA, PA-C, CDE

Presented by: Novo Nordisk

718 AB, Metro Toronto Convention Centre

 

Learning objectives:

  • Review current concepts around A1C
  • Emphasize the need for use of additional indices of overall glycemic control
  • Highlight the need to develop clinical skills to translate data into practice

 

 

Monday, May 28

 

Breakfast Product Theaters

 

7 - 7:45 a.m.

Middle-of-the-Night Awakenings: Matching Insomnia Therapy to Patient Need

Presented by: Purdue Pharma L.P.

701 AB, Metro Toronto Convention Centre

 

The Physician Assistant and treatment teams are critical to the diagnosis and appropriate management of insomnia. Attend the Product Theater “Middle-of-the-Night Awakenings: Matching Insomnia Therapy to Patient Need,” to learn about a newly-approved treatment option. This is a promotional event. CME will not be available.

 

7 - 7:45 a.m.

Approaches in Managing Mealtime Insulin in Primary Care: Why, When and How to Initiate Basal-Bolus Therapy

Presented by: Novo Nordisk

718 AB, Metro Toronto Convention Centre

 

Novo Nordisk and the National Diabetes Education Initiative® (NDEI®) have developed a compelling educational program that focuses on the management of type 2 diabetes in the primary care setting. This presentation will review the progressive nature of type 2 diabetes and describe the role of early intensification of insulin analog therapy toward achieving and maintaining adequate glycemic control. This is a promotional medical education presentation; it will not be certified for continuing medical education or continuing education credit.

 

Lunch Product Theaters

 

12 – 12:45 p.m.

Therapeutic Considerations for Successful Asthma Management

Speaker: Gabriel Ortiz, MPAS, PA-C, DFAAPA

Presented by: Teva Respiratory

701 AB, Metro Toronto Convention Centre

 

The “Therapeutic Considerations for Successful Asthma Management” presentation, sponsored by Teva Respiratory, will review applications of asthma controller therapy to optimize patient outcomes. This presentation will also review considerations for SABA therapy for patients with asthma, chronic obstructive pulmonary disease, and exercise-induced bronchospasm.

 

 

12 – 12:45 p.m.

Tradjenta™ (linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Speakers: Richard B. Aguilar, MD and James R. Gavin III, MD, PhD

Presented by: Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

718 AB, Metro Toronto Convention Centre

 

 

Tuesday, May 29

 

Breakfast Product Theater

 

7 - 7:45 a.m.

The First Buprenorphine Analgesic Transdermal System

Presented by: Purdue Pharma L.P.

701 AB, Metro Toronto Convention Centre

 

Full Prescribing Information, including the Boxed Warning, will be available at this event.

 

Lunch Product Theaters

 

12 - 12:45 p.m.

ACT NOW: The Importance of Intervention and Reducing Exacerbations in COPD

Speakers: Steve White, MD and Michael Van Buren Calvin, PA-C

Presented by: Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer, Inc.

701 AB, Metro Toronto Convention Centre

 

We invite you to an informative presentation that highlights the importance of recognizing at-risk patients with COPD, and the benefits of screening, diagnosis, and intervention. Experienced clinicians will review the significance of reducing COPD “flare-ups” or exacerbations, and a prescription maintenance treatment option to aid you in managing COPD in your patients will be discussed.

 

12 - 12:45 p.m.

Product Theater: A Case of Unexplained Abdominal Pain

Presented by: Viropharma Incorporated

718 AB, Metro Toronto Convention Centre

 

A case study of unexplained recurrent abdominal pain will be presented and the audience will be asked to make the diagnosis.

 

12 – 12:45pm

Diabetes Product Theater

Presented by: Takeda Pharmaceuticals U.S.A., Inc.

801 AB, Metro Toronto Convention Centre

 

Product Theater's Quick Links

 

 

Rocket Fuel